Cargando…

Assessment of the Response Profile to Hyaluronic Acid Plus Sorbitol Injection in Patients with Knee Osteoarthritis: Post-Hoc Analysis of a 6-Month Randomized Controlled Trial

In a previous randomized trial, the non-inferiority of two hyaluronic acid injections (Synolis VA versus Synvisc-One) was assessed in patients with knee OA, with a response rate of 79% for Synolis VA. To assess whether a responder profile could be established for this treatment modality, we used the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruyère, Olivier, Honvo, Germain, Vidovic, Eduard, Cortet, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533492/
https://www.ncbi.nlm.nih.gov/pubmed/34680131
http://dx.doi.org/10.3390/biom11101498
_version_ 1784587326233509888
author Bruyère, Olivier
Honvo, Germain
Vidovic, Eduard
Cortet, Bernard
author_facet Bruyère, Olivier
Honvo, Germain
Vidovic, Eduard
Cortet, Bernard
author_sort Bruyère, Olivier
collection PubMed
description In a previous randomized trial, the non-inferiority of two hyaluronic acid injections (Synolis VA versus Synvisc-One) was assessed in patients with knee OA, with a response rate of 79% for Synolis VA. To assess whether a responder profile could be established for this treatment modality, we used the Synolis VA arm of a published 6-month prospective, multicenter, comparative, randomized, double-blinded trial. At baseline and during the study, pain and function were assessed using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) questionnaire. Ninety-six subjects from the intention-to-treat trial were included in the analysis. The 6-month change of WOMAC Pain with Synolis VA was not associated with any baseline clinical data. However, the change in WOMAC Function was significantly associated with its baseline level, even after adjustment for potential confounding variables (p = 0.028), i.e., a poorer physical function at baseline was associated with a better response. In conclusion, in addition to the high absolute response rate to Synolis VA, the probability of success is even increased if administered in patients with more limited physical function at baseline. Further research with other potential confounding clinical variables is warranted in order to better applicate the concept of personalized medicine.
format Online
Article
Text
id pubmed-8533492
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85334922021-10-23 Assessment of the Response Profile to Hyaluronic Acid Plus Sorbitol Injection in Patients with Knee Osteoarthritis: Post-Hoc Analysis of a 6-Month Randomized Controlled Trial Bruyère, Olivier Honvo, Germain Vidovic, Eduard Cortet, Bernard Biomolecules Article In a previous randomized trial, the non-inferiority of two hyaluronic acid injections (Synolis VA versus Synvisc-One) was assessed in patients with knee OA, with a response rate of 79% for Synolis VA. To assess whether a responder profile could be established for this treatment modality, we used the Synolis VA arm of a published 6-month prospective, multicenter, comparative, randomized, double-blinded trial. At baseline and during the study, pain and function were assessed using the Western Ontario and McMaster Universities Arthritis Index (WOMAC) questionnaire. Ninety-six subjects from the intention-to-treat trial were included in the analysis. The 6-month change of WOMAC Pain with Synolis VA was not associated with any baseline clinical data. However, the change in WOMAC Function was significantly associated with its baseline level, even after adjustment for potential confounding variables (p = 0.028), i.e., a poorer physical function at baseline was associated with a better response. In conclusion, in addition to the high absolute response rate to Synolis VA, the probability of success is even increased if administered in patients with more limited physical function at baseline. Further research with other potential confounding clinical variables is warranted in order to better applicate the concept of personalized medicine. MDPI 2021-10-11 /pmc/articles/PMC8533492/ /pubmed/34680131 http://dx.doi.org/10.3390/biom11101498 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bruyère, Olivier
Honvo, Germain
Vidovic, Eduard
Cortet, Bernard
Assessment of the Response Profile to Hyaluronic Acid Plus Sorbitol Injection in Patients with Knee Osteoarthritis: Post-Hoc Analysis of a 6-Month Randomized Controlled Trial
title Assessment of the Response Profile to Hyaluronic Acid Plus Sorbitol Injection in Patients with Knee Osteoarthritis: Post-Hoc Analysis of a 6-Month Randomized Controlled Trial
title_full Assessment of the Response Profile to Hyaluronic Acid Plus Sorbitol Injection in Patients with Knee Osteoarthritis: Post-Hoc Analysis of a 6-Month Randomized Controlled Trial
title_fullStr Assessment of the Response Profile to Hyaluronic Acid Plus Sorbitol Injection in Patients with Knee Osteoarthritis: Post-Hoc Analysis of a 6-Month Randomized Controlled Trial
title_full_unstemmed Assessment of the Response Profile to Hyaluronic Acid Plus Sorbitol Injection in Patients with Knee Osteoarthritis: Post-Hoc Analysis of a 6-Month Randomized Controlled Trial
title_short Assessment of the Response Profile to Hyaluronic Acid Plus Sorbitol Injection in Patients with Knee Osteoarthritis: Post-Hoc Analysis of a 6-Month Randomized Controlled Trial
title_sort assessment of the response profile to hyaluronic acid plus sorbitol injection in patients with knee osteoarthritis: post-hoc analysis of a 6-month randomized controlled trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533492/
https://www.ncbi.nlm.nih.gov/pubmed/34680131
http://dx.doi.org/10.3390/biom11101498
work_keys_str_mv AT bruyereolivier assessmentoftheresponseprofiletohyaluronicacidplussorbitolinjectioninpatientswithkneeosteoarthritisposthocanalysisofa6monthrandomizedcontrolledtrial
AT honvogermain assessmentoftheresponseprofiletohyaluronicacidplussorbitolinjectioninpatientswithkneeosteoarthritisposthocanalysisofa6monthrandomizedcontrolledtrial
AT vidoviceduard assessmentoftheresponseprofiletohyaluronicacidplussorbitolinjectioninpatientswithkneeosteoarthritisposthocanalysisofa6monthrandomizedcontrolledtrial
AT cortetbernard assessmentoftheresponseprofiletohyaluronicacidplussorbitolinjectioninpatientswithkneeosteoarthritisposthocanalysisofa6monthrandomizedcontrolledtrial